ProKidney Corp. (PROK) has been beaten down lately with too much selling pressure. While the stock has lost 38% over the past four weeks, there is light at the end of the tunnel as it is now in ...

ProKidney Corp. targets diabetic CKD with Rilparencel and expects Q2 2027 eGFR slope data for accelerated approval. Find out ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell ...

ProKidney Corp. (PROK) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

ProKidney Corp. (NASDAQ:PROK) stock is trading higher on Tuesday, with a session volume of 39.8 million compared to the average volume of 1.12 million as per data from Benzinga Pro. What happened: The ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in SoundHound AI Inc (Symbol: SOUN), where a total volume of 360,873 contracts has ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Shares of ProKidney Corp. PROK skyrocketed 515% yesterday after the company reported encouraging top-line data from the phase II REGEN-007 study evaluating its lead pipeline drug, rilparencel, in ...